Asset profile
astegolimab
Monoclonal antibody
Evidence outlook · registrational
Chronic Obstructive Pulmonary Disease: registrational readout pending
Entered Phase 3 on partial signal mid-stage evidence. Registrational readout expected around 2027-06-30.
NCT05037929: The trial randomly assigned 1,334 participants to astegolimab or placebo and masked both participants and investigators. Its primary endpoint was the annualized rate of moderate and severe COPD exacerbations, a hard clinical outcome, but no results are available to determine whether the comparison was favorable.
Primary endpoint met for the every-two-weeks regimen only (Lancet: 15% reduction, p=0.0494); the every-four-weeks arm was not statistically significant.
Also in development:Atopic Dermatitis · Phase 2
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov — registry estimates, never confirmed readout dates; they can move as trials progress.
2027 (1)
June 2027 (1)
What to watch
Research analysis
Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.
Sign in to access ResearchAll registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.